<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537404</url>
  </required_header>
  <id_info>
    <org_study_id>CJ05013019</org_study_id>
    <nct_id>NCT03537404</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs</brief_title>
  <official_title>A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Almedis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction,
      safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and
      Tenofovir disoproxil fumarate (part 1) and Narlaprevir, Ritonavir and Raltegravir (part 2)
      are administered in combination to healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study includes 2 parts, as the following drugs may be used concomitantly to treat
      hepatitis C virus (HCV)/HIV coinfection:

        -  Part 1 of the study is being conducted to evaluate the pharmacokinetic effect of
           coadministration of narlaprevir with ritonavir and tenofovir disoproxil fumarate.

        -  Part 2 of the study is being conducted to evaluate the pharmacokinetic effect of
           coadministration of narlaprevir/ritonavir and raltegravir.

      Each part of the study is designed as a randomized 3-period crossover study and will assess
      if there is any effect of tenofovir disoproxil fumarate or raltegravir on the
      pharmacokinetics of narlaprevir and vice versa.

      Subjects will be screened within 28 days before dosing in this multi-part study. All subjects
      eligible for protocol criteria will be randomized 1:1:1 to receive one of the following
      treatment sequences: A/B/C, or B/C/A, or C/A/B. Every subject will receive only one treatment
      (A or B or C) in one Period. Subjects will be confined to the study center throughout
      treatment in each period. Following completion of study procedures for each treatment period,
      subjects will be released from the clinic. After a 7-14 (maximum) days interval between
      dosing, subjects will return to start hospitalization for the next treatment period. Subjects
      will be discharged from the study upon completion of all study related procedures in Period
      3. Phone call will be conducted after 5-7 days of follow-up period to assess safety data.

      This drug interaction study is designed to investigate pharmacokinetic drug-drug interactions
      between Narlaprevir coadministered with Ritonavir and antiretroviral drugs (Tenofovir
      disoproxil fumarate and Raltegravir) for labeling and clinical dosing guidance purposes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Narlaprevir</measure>
    <time_frame>Day 5 Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 5 of treatment A and C (Part 1/ Part 2)</time_frame>
    <description>Maximum observed Concentration of Narlaprevir at Day 5 of treatment A and C of Part 1 or 2 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau of Narlaprevir</measure>
    <time_frame>Day 5 Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 5 of treatment A and C (Part 1/ Part 2)</time_frame>
    <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Narlaprevir at Day 5 of treatment A and C of Part 1/ Part 2 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Tenofovir</measure>
    <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 18 and 24 hrs post-dose on Day 5 of treatment B and C (Part 1)</time_frame>
    <description>Maximum observed Concentration of Tenofovir at Day 5 of treatment B and C of Part 1 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau of Tenofovir</measure>
    <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 18 and 24 hrs post-dose on Day 5 of treatment B and C (Part 1)</time_frame>
    <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Tenofovir at Day 5 of treatment B and C of Part 1 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Raltegravir</measure>
    <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12 hrs post-dose of Day 5 of treatment B and C (Part 2)</time_frame>
    <description>Maximum observed Concentration of Raltegravir at Day 5 of treatment B and C of Part 2 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau of Raltegravir</measure>
    <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12 hrs post-dose of Day 5 of treatment B and C (Part 2)</time_frame>
    <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Tenofovir at Day 5 of treatment B and C of Part 2 of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Changes in Vital Signs</measure>
    <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
    <description>There were no subjects with abnormal changes in vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal Laboratory Values</measure>
    <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Abnormal ECG Changes</measure>
    <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
    <description>There were no subjects with abnormal ECG changes during the study</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A (Part 1/ Part 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B (Part 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir disoproxil fumarate 300 mg once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B (Part 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400 mg twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Narlaprevir</intervention_name>
    <description>100 mg, film-coated tablets, taken as 200 mg per os daily</description>
    <arm_group_label>Treatment A (Part 1/ Part 2)</arm_group_label>
    <arm_group_label>Treatment C (Part 1)</arm_group_label>
    <arm_group_label>Treatment C (Part 2)</arm_group_label>
    <other_name>Arlansa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100 mg, film-coated tablets, taken as 100 mg per os daily</description>
    <arm_group_label>Treatment A (Part 1/ Part 2)</arm_group_label>
    <arm_group_label>Treatment C (Part 1)</arm_group_label>
    <arm_group_label>Treatment C (Part 2)</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>300 mg, film-coated tablets, taken as 300 mg per os daily</description>
    <arm_group_label>Treatment B (Part 1)</arm_group_label>
    <arm_group_label>Treatment C (Part 1)</arm_group_label>
    <other_name>Tenofovir-TL</other_name>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400 mg, film-coated tablets, taken as 400 mg per os daily</description>
    <arm_group_label>Treatment B (Part 2)</arm_group_label>
    <arm_group_label>Treatment C (Part 2)</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (the subject must meet all the criteria listed below for entry at
        baseline and at Days -1 and 1 before each treatment Period):

          -  Subjects must be willing to give written informed consent for the trial and able to
             adhere to dose and visit schedules.

          -  Subjects having a Body Mass Index (BMI) between 18,5 and 30 kg/m^2, inclusive.

          -  Subjects should diagnosed as &quot;healthy&quot;: no pathology of the gastrointestinal tract,
             liver, kidneys, cardiovascular system, central nervous system (previously carried out
             by standard clinical and lab tests which did not reveal the presence of any diseases.
             Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must not exceed
             the normal range; QT interval calculated by Bazett's formula (QTcB) for men should be
             ≤ 450 ms and ≤ 470 ms for women, the interval PR should be ≤ 200 ms).

          -  Vital sign measurements (taken after ~3 minutes in a supine or sitting position) must
             be within the following ranges:

               1. systolic blood pressure, 100 - 130 mm Hg;

               2. diastolic blood pressure, 60 -90 mm Hg;

               3. pulse rate, 60-80 bpm.

          -  Female subjects must be:

               1. postmenopausal (defined as 12 months with no menses; age &gt; 40 years and with a
                  follicle-stimulating hormone (FSH) level of &gt;40 u/mL);

               2. surgically sterilized at least 3 months prior to baseline (e.g., documented
                  hysterectomy or tubal ligation).

          -  Men must agree to use a medically accepted method of contraception (condom and
             spermicide) during the trial and for 3 months after stopping the medication.

        Exclusion Criteria (the subject will be excluded from entry if any of the criteria listed
        below are met at baseline):

          -  Females with childbearing potential.

          -  Subjects who, in the opinion of the investigator, will not be able to participate
             optimally in the study.

          -  Positive results for hepatitis B surface antigen, hepatitis C antibodies or HIV,
             positive RW results.

          -  Allergic reactions in history.

          -  Intolerance to medication.

          -  Chronic disease of cardiovascular, bronchopulmonary, and/or neuroendocrine systems,
             gastrointestinal, liver, pancreas, kidney and/or blood disease.

          -  History or presence of impaired renal function, lactase deficiency, lactose
             intolerance, glucose-galactose malabsorption.

          -  History of urinary obstruction or difficulty in voiding.

          -  Gastrointestinal surgery in history (except of appendectomy).

          -  Acute infections less than 4 weeks before participation in the study.

          -  Subjects with a medical history of osteopenia and/or osteoporosis.

          -  Regular administration of any medicines less than 4 weeks before participation in the
             study.

          -  Administration of medicines with marked influence on hemodynamics, liver function et
             al (barbiturates, omeprazole, cimetidine et al) less than 30 days before participation
             in the study.

          -  Blood donation (450 ml or more of blood or plasma) less than 2 months before
             participation in the study.

          -  Intake of more than 10 units of alcohol in a week (1 unit of alcohol is equal to 0.5 L
             of beer, 200 mL of wine or 50 mL of spirits) or history of drug abuse or alcoholism.

          -  Smoking of more than 10 cigarettes or equivalent tobacco use per day.

          -  Participation in phase 1 clinical trial less than 3 months before participation in the
             study.

          -  Positive screen for drugs abuse and drugs use.

          -  Subjects with a medical history of psychiatric or personality disorders that in the
             opinion of the investigator and sponsor, affects the subject's ability to participate
             in the trial.

          -  Subjects who are part of the study staff personnel or family members of the study
             staff personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Samsonov</last_name>
    <role>Study Director</role>
    <affiliation>R-Pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic &quot;Bessalar&quot; JSC</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <results_first_submitted>August 31, 2018</results_first_submitted>
  <results_first_submitted_qc>August 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2019</results_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>chronic</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>HIV</keyword>
  <keyword>coinfection</keyword>
  <keyword>concomitant therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03537404/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult volunteers were recruited for all Parts of the study in one clinical site (Bessalar clinic) in Moscow between April and June 2017. 36 subjects were randomized so that 18 subjects participated in each Part of the study (6 subjects in each treatment group of each Part).</recruitment_details>
      <pre_assignment_details>Subjects were to be screened within 28 days before dosing in this multi-part study. Subjects were to be admitted to the study center the evening before the first dose for baseline assessments to confirm eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1</title>
          <description>All patients of Part 1 of the study were randomized in 1:1:1 ratio to receive one of the treatment sequences (A/B/C, B/C/A or C/A/B). Every subject received only one drug combination (A or B or C) in one treatment period. Each period was followed by 8 washout days. Treatments include:
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily); Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily); Tenofovir Disoproxil Fumarate (300 mg, film-coated tablets, taken as 300 mg per os once daily) in different combinations assigned to the subjects in accordance with protocol considerations for Part 1 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Part 2</title>
          <description>All patients of Part 2 of the study were randomized in 1:1:1 ratio to receive one of the treatment sequences (A/B/C, B/C/A or C/A/B). Every subject received only one drug combination (A or B or C) in one treatment period. Each period was followed by 8 washout days. Treatments include:
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily); Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily); Raltegravir (400 mg, film-coated tablets, taken as 400 mg per os once daily) in different combinations assigned to the subjects in accordance with protocol considerations for Part 2 of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (A or B or C)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Washout Period (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (A or B or C)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Washout Period (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (A or B or C)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 36 subjects randomized to study treatment and received at least one dose of study drug (Safety Population).</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence A/B/C</title>
          <description>All participants of Part 1 or 2 of the study randomized in this group received treatment combinations (according to the protocol allocation) in the following sequence:
Treatment period 1 - Treatment A Treatment period 2 - Treatment B Treatment period 3 - Treatment C</description>
        </group>
        <group group_id="B2">
          <title>Sequence B/C/A</title>
          <description>All participants of Part 1 or 2 of the study randomized in this group received treatment combinations (according to the protocol allocation) in the following sequence:
Treatment period 1 - Treatment B Treatment period 2 - Treatment C Treatment period 3 - Treatment A</description>
        </group>
        <group group_id="B3">
          <title>Sequence C/A/B</title>
          <description>All participants of Part 1 or 2 of the study randomized in this group received treatment combinations (according to the protocol allocation) in the following sequence:
Treatment period 1 - Treatment C Treatment period 2 - Treatment A Treatment period 3 - Treatment B</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Baseline characteristics analisys was performed separately for Part 1 and 2 of the study (18 subjects in each Part were randomized in 1:1:1 ratio for each treatment sequence - 6 participants in each).</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="1.75"/>
                    <measurement group_id="B2" value="38.3" spread="8.26"/>
                    <measurement group_id="B3" value="29.7" spread="1.86"/>
                    <measurement group_id="B4" value="30.8" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="4.03"/>
                    <measurement group_id="B2" value="38.7" spread="4.59"/>
                    <measurement group_id="B3" value="29.5" spread="3.33"/>
                    <measurement group_id="B4" value="30.8" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Baseline characteristics analisys was performed separately for Part 1 and 2 of the study (18 subjects in each Part were randomized in 1:1:1 ratio for each treatment sequence - 6 participants in each).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Baseline characteristics analisys was performed separately for Part 1 and 2 of the study (18 subjects in each Part were randomized in 1:1:1 ratio for each treatment sequence - 6 participants in each).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Calculated as weight(kg)/height(m^2)</description>
          <population>Baseline characteristics analisys was performed separately for Part 1 and 2 of the study (18 subjects in each Part were randomized in 1:1:1 ratio for each treatment sequence - 6 participants in each).</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.14" spread="1.287"/>
                    <measurement group_id="B2" value="24.73" spread="3.022"/>
                    <measurement group_id="B3" value="24.20" spread="3.134"/>
                    <measurement group_id="B4" value="24.02" spread="2.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.26" spread="4.132"/>
                    <measurement group_id="B2" value="25.40" spread="2.732"/>
                    <measurement group_id="B3" value="25.63" spread="3.408"/>
                    <measurement group_id="B4" value="25.10" spread="3.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Narlaprevir</title>
        <description>Maximum observed Concentration of Narlaprevir at Day 5 of treatment A and C of Part 1 or 2 of the study</description>
        <time_frame>Day 5 Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 5 of treatment A and C (Part 1/ Part 2)</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Part 1)</title>
            <description>Subjects in both Parts of the study recieved as Treatment A for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) and Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily).</description>
          </group>
          <group group_id="O2">
            <title>Treatment C (Part 1)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily) and Tenofovir Disoproxil Fumarate (300 mg, film-coated tablets, taken as 300 mg per os once daily).</description>
          </group>
          <group group_id="O3">
            <title>Treatment A (Part 2)</title>
            <description>Subjects in both Parts of the study recieved as Treatment A for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) and Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily).</description>
          </group>
          <group group_id="O4">
            <title>Treatment C (Part 2)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily and Raltegravir (400 mg, film-coated tablets, taken as 400 mg per os twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Narlaprevir</title>
          <description>Maximum observed Concentration of Narlaprevir at Day 5 of treatment A and C of Part 1 or 2 of the study</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2130.2742" lower_limit="1817.4088" upper_limit="2731.8348"/>
                    <measurement group_id="O2" value="2172.233" lower_limit="1895.673" upper_limit="2726.557"/>
                    <measurement group_id="O3" value="2946.131" lower_limit="2617.485" upper_limit="3799.642"/>
                    <measurement group_id="O4" value="2880.612" lower_limit="2412.858" upper_limit="4121.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.020</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.103</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
            <estimate_desc>Cmax parameters were logarithmically transformed</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>-0.022</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.220</ci_lower_limit>
            <ci_upper_limit>0.175</ci_upper_limit>
            <estimate_desc>Cmax parameters were logarithmically transformed</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCtau of Narlaprevir</title>
        <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Narlaprevir at Day 5 of treatment A and C of Part 1/ Part 2 of the study</description>
        <time_frame>Day 5 Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 5 of treatment A and C (Part 1/ Part 2)</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Part 1)</title>
            <description>Subjects in both Parts of the study recieved as Treatment A for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) and Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily).</description>
          </group>
          <group group_id="O2">
            <title>Treatment C (Part 1)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily) and Tenofovir Disoproxil Fumarate (300 mg, film-coated tablets, taken as 300 mg per os once daily).</description>
          </group>
          <group group_id="O3">
            <title>Treatment A (Part 2)</title>
            <description>Subjects in both Parts of the study recieved as Treatment A for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) and Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily).</description>
          </group>
          <group group_id="O4">
            <title>Treatment C (Part 2)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily and Raltegravir (400 mg, film-coated tablets, taken as 400 mg per os twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>AUCtau of Narlaprevir</title>
          <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Narlaprevir at Day 5 of treatment A and C of Part 1/ Part 2 of the study</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
          <units>ng*h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20504.31" lower_limit="18265.63" upper_limit="24328.95"/>
                    <measurement group_id="O2" value="21366.2" lower_limit="18664.1" upper_limit="26481.9"/>
                    <measurement group_id="O3" value="26199.19" lower_limit="23136.15" upper_limit="33132.53"/>
                    <measurement group_id="O4" value="24458.48" lower_limit="20738.76" upper_limit="33597.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.041</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.075</ci_lower_limit>
            <ci_upper_limit>0.157</ci_upper_limit>
            <estimate_desc>AUCtau parameters were logarithmically transformed.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>-0.069</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.201</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
            <estimate_desc>AUCtau parameters were logarithmically transformed</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Tenofovir</title>
        <description>Maximum observed Concentration of Tenofovir at Day 5 of treatment B and C of Part 1 of the study</description>
        <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 18 and 24 hrs post-dose on Day 5 of treatment B and C (Part 1)</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B (Part 1)</title>
            <description>Subjects recieved as Treatment B for 5 days (in respective treatment period):
Tenofovir Disoproxil Fumarate (300 mg, film-coated tablets, taken as 300 mg per os once daily).</description>
          </group>
          <group group_id="O2">
            <title>Treatment C (Part 1)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily) and Tenofovir Disoproxil Fumarate (300 mg, film-coated tablets, taken as 300 mg per os once daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Tenofovir</title>
          <description>Maximum observed Concentration of Tenofovir at Day 5 of treatment B and C of Part 1 of the study</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.037" lower_limit="233.126" upper_limit="313.318"/>
                    <measurement group_id="O2" value="344.796" lower_limit="302.457" upper_limit="415.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.271</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.159</ci_lower_limit>
            <ci_upper_limit>0.383</ci_upper_limit>
            <estimate_desc>Cmax parameters were logarithmically transformed</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCtau of Tenofovir</title>
        <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Tenofovir at Day 5 of treatment B and C of Part 1 of the study</description>
        <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 18 and 24 hrs post-dose on Day 5 of treatment B and C (Part 1)</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B (Part 1)</title>
            <description>Subjects recieved as Treatment B for 5 days (in respective treatment period):
Tenofovir Disoproxil Fumarate (300 mg, film-coated tablets, taken as 300 mg per os once daily).</description>
          </group>
          <group group_id="O2">
            <title>Treatment C (Part 1)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily) and Tenofovir Disoproxil Fumarate (300 mg, film-coated tablets, taken as 300 mg per os once daily).</description>
          </group>
        </group_list>
        <measure>
          <title>AUCtau of Tenofovir</title>
          <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Tenofovir at Day 5 of treatment B and C of Part 1 of the study</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
          <units>ng*h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2599.95" lower_limit="2325.72" upper_limit="3043.02"/>
                    <measurement group_id="O2" value="2799.72" lower_limit="2536.67" upper_limit="3205.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.074</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>AUCtau parameters were logarithmically transformed</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Raltegravir</title>
        <description>Maximum observed Concentration of Raltegravir at Day 5 of treatment B and C of Part 2 of the study</description>
        <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12 hrs post-dose of Day 5 of treatment B and C (Part 2)</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B (Part 2)</title>
            <description>Subjects recieved as Treatment B for 5 days (in respective treatment period):
Raltegravir (400 mg, film-coated tablets, taken as 400 mg per os twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Treatment C (Part 2)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily and Raltegravir (400 mg, film-coated tablets, taken as 400 mg per os twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Raltegravir</title>
          <description>Maximum observed Concentration of Raltegravir at Day 5 of treatment B and C of Part 2 of the study</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830.204" lower_limit="520.042" upper_limit="2758.109"/>
                    <measurement group_id="O2" value="715.726" lower_limit="136.163" upper_limit="2396.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>-0.148</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.450</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>Cmax parameters were logarithmically transformed</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCtau of Raltegravir</title>
        <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Tenofovir at Day 5 of treatment B and C of Part 2 of the study</description>
        <time_frame>Day 5 Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12 hrs post-dose of Day 5 of treatment B and C (Part 2)</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B (Part 2)</title>
            <description>Subjects recieved as Treatment B for 5 days (in respective treatment period):
Raltegravir (400 mg, film-coated tablets, taken as 400 mg per os twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Treatment C (Part 2)</title>
            <description>Subjects recieved as Treatment C for 5 days (in respective treatment period):
Narlaprevir (100 mg, film-coated tablets, taken as 200 mg per os once daily) coadministered with Ritonavir (100 mg, film-coated tablets, taken as 100 mg per os once daily and Raltegravir (400 mg, film-coated tablets, taken as 400 mg per os twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>AUCtau of Raltegravir</title>
          <description>Area Under the Concentration-time curve during a dosing interval τ at steady state of Tenofovir at Day 5 of treatment B and C of Part 2 of the study</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug.</population>
          <units>ng*h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2912.45" lower_limit="1983.01" upper_limit="8451.44"/>
                    <measurement group_id="O2" value="2653.65" lower_limit="1033.88" upper_limit="6964.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>-0.093</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.354</ci_lower_limit>
            <ci_upper_limit>0.168</ci_upper_limit>
            <estimate_desc>AUCtau parameters were logarithmically transformed</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Part 1)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Part 1)</title>
            <description>Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C (Part 1)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily
coadministered with
Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily
and
Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment A (Part 2)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Treatment B (Part 2)</title>
            <description>Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
          </group>
          <group group_id="O6">
            <title>Treatment C (Part 2)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily
coadministered with
Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily
and
Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <population>All subjects randomized to study treatment and received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Changes in Vital Signs</title>
        <description>There were no subjects with abnormal changes in vital signs</description>
        <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Part 1)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Part 1)</title>
            <description>Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C (Part 1)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily
coadministered with
Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily
and
Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment A (Part 2)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
          </group>
          <group group_id="O5">
            <title>Treatment B (Part 2)</title>
            <description>Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
          </group>
          <group group_id="O6">
            <title>Treatment C (Part 2)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily
coadministered with
Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily
and
Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Changes in Vital Signs</title>
          <description>There were no subjects with abnormal changes in vital signs</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal Laboratory Values</title>
        <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug separately for each Patr of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Part 1)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Part 1)</title>
            <description>Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C (Part 1)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily
coadministered with
Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily
and
Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal Laboratory Values</title>
          <population>All subjects randomized to study treatment and received at least one dose of study drug separately for each Patr of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Abnormal ECG Changes</title>
        <description>There were no subjects with abnormal ECG changes during the study</description>
        <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
        <population>All subjects randomized to study treatment and received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A (Part 1/Part 2)</title>
            <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (Part 1/Part 2)</title>
            <description>Part 1: Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days
Part 2: Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C (Part 1/Part 2)</title>
            <description>Part 1: Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily coadministered with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily and Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days
Part 2: Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily coadministered with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily and Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Abnormal ECG Changes</title>
          <description>There were no subjects with abnormal ECG changes during the study</description>
          <population>All subjects randomized to study treatment and received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 Days after the last dose of treatment in period 3 of each Part of the Study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A (Part 1)</title>
          <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Treatment B (Part 1)</title>
          <description>Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Treatment C (Part 1)</title>
          <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily
coadministered with
Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily
and
Tenofovir Disoproxil Fumarate, 300 mg, film-coated tablets, taken as 300 mg per os daily for 5 days</description>
        </group>
        <group group_id="E4">
          <title>Treatment A (Part 2)</title>
          <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily in combination with Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily for 5 days</description>
        </group>
        <group group_id="E5">
          <title>Treatment B (Part 2)</title>
          <description>Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
        </group>
        <group group_id="E6">
          <title>Treatment C (Part 2)</title>
          <description>Narlaprevir, 100 mg, film-coated tablets, taken as 200 mg per os daily
coadministered with
Ritonavir, 100 mg, film-coated tablets, taken as 100 mg per os daily
and
Raltegravir, 400 mg, film-coated tablets, taken as 400 mg per os daily for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any study related information could be made public availiable only after Sponsors written permission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emiliya Krasavina, Medical Adviser</name_or_title>
      <organization>R-Pharm</organization>
      <phone>0074959567937</phone>
      <email>krasavina@rpharm.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

